Fenwick Represents Scribe Therapeutics in Strategic Collaboration with Sanofi

Fenwick represented Scribe Therapeutics, a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, in its strategic collaboration and licensing agreement with Sanofi, a global healthcare company, for the use of Scribe’s CRISPR genome editing technologies to enable genetic modification of novel natural killer (NK) cell therapies for cancer.

Under the terms of the agreement, Scribe will receive $25 million in upfront payment and be eligible to potentially receive more than $1 billion in payments based on development and commercial milestones, as well as tiered royalties on net future sales on any products that may result from this research agreement. More information about the collaboration can be obtained from the announcement.

The Fenwick transaction team was led by life sciences partner Stefano Quintini and included partners Jake Handy and Daniel Becker.​​